These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 19421040)
21. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. O'Brien TP; Arshinoff SA; Mah FS J Cataract Refract Surg; 2007 Oct; 33(10):1790-800. PubMed ID: 17889778 [TBL] [Abstract][Full Text] [Related]
22. Safety of moxifloxacin and voriconazole in corneal storage media on porcine corneal endothelial cells. Kim SY; Yang J; Lee YC J Ocul Pharmacol Ther; 2010 Aug; 26(4):315-8. PubMed ID: 20698796 [TBL] [Abstract][Full Text] [Related]
23. The protective effect of quercetin against oxidative stress in the human RPE in vitro. Kook D; Wolf AH; Yu AL; Neubauer AS; Priglinger SG; Kampik A; Welge-Lüssen UC Invest Ophthalmol Vis Sci; 2008 Apr; 49(4):1712-20. PubMed ID: 18385095 [TBL] [Abstract][Full Text] [Related]
24. Growth-related effects of oxidant-induced stress on cultured RPE and choroidal endothelial cells. Eichler W; Reiche A; Yafai Y; Lange J; Wiedemann P Exp Eye Res; 2008 Oct; 87(4):342-8. PubMed ID: 18640112 [TBL] [Abstract][Full Text] [Related]
25. The effect of cataract surgery on ocular levels of topical moxifloxacin. Mather R; Stewart JM; Prabriputaloong T; Wong J; McLeod SD Am J Ophthalmol; 2004 Oct; 138(4):554-9. PubMed ID: 15488780 [TBL] [Abstract][Full Text] [Related]
26. Intravitreal moxifloxacin: retinal safety study with electroretinography and histopathology in animal models. Gao H; Pennesi ME; Qiao X; Iyer MN; Wu SM; Holz ER; Mieler WF Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1606-11. PubMed ID: 16565399 [TBL] [Abstract][Full Text] [Related]
27. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Lai WW; Chu KO; Chan KP; Choy KW; Wang CC; Tsang CW; Pang CP Am J Ophthalmol; 2007 Aug; 144(2):315-8. PubMed ID: 17659971 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. Kim SY; Park YH; Lee YC Clin Exp Ophthalmol; 2008 May; 36(4):367-70. PubMed ID: 18700925 [TBL] [Abstract][Full Text] [Related]
29. [Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells]. Kernt M; Welge-Lüssen U; Yu A; Neubauer AS; Kampik A Ophthalmologe; 2007 Nov; 104(11):965-71. PubMed ID: 17653724 [TBL] [Abstract][Full Text] [Related]
30. Comparison of in vitro safety profiles of vancomycin and cefuroxime on human corneal endothelial cells for intracameral use. Yoeruek E; Spitzer MS; Saygili O; Tatar O; Biedermann T; Yoeruek E; Bartz-Schmidt KU; Szurman P J Cataract Refract Surg; 2008 Dec; 34(12):2139-45. PubMed ID: 19027573 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal clearance of moxifloxacin. Iyer MN; He F; Wensel TG; Mieler WF; Benz MS; Holz ER Trans Am Ophthalmol Soc; 2005; 103():76-81; discussion 81-3. PubMed ID: 17057790 [TBL] [Abstract][Full Text] [Related]
32. Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. Valamanesh F; Torriglia A; Savoldelli M; Gandolphe C; Jeanny JC; BenEzra D; Behar-Cohen F Mol Vis; 2007 Sep; 13():1746-57. PubMed ID: 17960113 [TBL] [Abstract][Full Text] [Related]
33. Comparison of toxicities of moxifloxacin, cefuroxime, and levofloxacin to corneal endothelial cells in vitro. Haruki T; Miyazaki D; Matsuura K; Terasaka Y; Noguchi Y; Inoue Y; Yamagami S J Cataract Refract Surg; 2014 Nov; 40(11):1872-8. PubMed ID: 25262563 [TBL] [Abstract][Full Text] [Related]
35. Corneal endothelial cell survival in organ cultures under acute oxidative stress: effect of VIP. Koh SW; Waschek JA Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4085-92. PubMed ID: 11095600 [TBL] [Abstract][Full Text] [Related]
36. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Kowalski RP; Romanowski EG; Mah FS; Yates KA; Gordon YJ Am J Ophthalmol; 2004 Jul; 138(1):33-7. PubMed ID: 15234279 [TBL] [Abstract][Full Text] [Related]
37. The effect of moxifloxacin on the normal human cornea. Donaldson KE; Marangon FB; Schatz L; Venkatraman AS; Alfonso EC Curr Med Res Opin; 2006 Oct; 22(10):2073-80. PubMed ID: 17022866 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of moxifloxacin as an additive in Optisol-GS a preservation medium for corneal donor tissue. Ritterband DC; Shah MK; Meskin SW; Shapiro DE; Seedor JA; Koplin RS; Hu DN; Shao S; Dahl P; McCormick S Cornea; 2006 Oct; 25(9):1084-9. PubMed ID: 17133059 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of intravenously administered moxifloxacin in eye compartments: an experimental study. Tzepi I; Vergados I; Kanellakopoulou K; Papathanassiou M; Kranidioti H; Tsaganos T; Liarakos V; Giamarellos-Bourboulis EJ; Theodossiadis P Int J Antimicrob Agents; 2009 Feb; 33(2):160-2. PubMed ID: 18947985 [TBL] [Abstract][Full Text] [Related]
40. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Robertson SM; Curtis MA; Schlech BA; Rusinko A; Owen GR; Dembinska O; Liao J; Dahlin DC Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]